Cantor Fitzgerald raises target for Eli Lilly stock to USD 1,440

Published on 10/09/2026 at 15:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue hit USD 22.97 billion, up 47.70 percent year over year. Eli Lilly stock costs EUR 1,039.50 on October 9, 2026 after EUR 1,040.80.

Key points in brief

Cantor Fitzgerald raised Eli Lilly's price target from USD 1,410.00 to USD 1,440.00 on October 9, 2026 while keeping an Overweight rating.
Second-quarter 2026 revenue reached USD 22.97 billion, up 47.70 percent year over year, and 2026 revenue guidance stood at USD 85.00 billion to USD 87.00 billion.
Eli Lilly stock was trading at EUR 1,039.50 at Lang & Schwarz on October 9, 2026, down 0.12 percent versus the EUR 1,040.80 prior close.
The primary exchange is the NYSE, with a USD 783.85 to USD 1,292.65 52-week range.

Aquarellmalerei eines CVD-Deposition-Tools in zarten Blau- und Silbertönen, ein Techniker steht an der Bedienkonsole — Lam Research US5324571083 Deposition Tool als zartes blaues Aquarell mit Techniker im hellen Reinraum, Illustration mit AI erstellt.

Eli Lilly and Co. (US5324571083) was trading at EUR 1,039.50 at Lang & Schwarz on October 9, 2026 at 3:35 p.m. CEST, down 0.12 percent versus the prior close of EUR 1,040.80. According to 24/7 Wall St. on October 9, 2026, Cantor Fitzgerald raised its target from USD 1,410.00 to USD 1,440.00 and kept an Overweight rating.

Target rises as revenue accelerates

The target increase followed Lilly's second-quarter 2026 revenue of USD 22.97 billion, up 47.70 percent from the same quarter a year earlier. The same report said Lilly's 2026 revenue guidance stood at USD 85.00 billion to USD 87.00 billion, giving the analyst action a clearly quantified operating backdrop.

What does the target imply?

The USD 1,440.00 target lies 23.76 percent above the USD 1,163.58 primary-exchange price cited for Lilly at 9:40 a.m. ET on October 9, 2026. MarketBeat identified the listing as NYSE:LLY and reported a USD 783.85 to USD 1,292.65 52-week range, putting the target above the current yearly high as well as the quoted market price.

Chronology brings three target moves

On September 15, 2026, Berenberg set a USD 1,400.00 target and a Buy rating, as reported by MarketBeat. On October 7, 2026, Morgan Stanley raised its target from USD 1,419.00 to USD 1,430.00 while maintaining Overweight, according to MarketBeat. On October 9, 2026, Cantor Fitzgerald moved its target from USD 1,410.00 to USD 1,440.00 and retained Overweight, according to 24/7 Wall St..

Upcoming reporting date

Eli Lilly's next reported event is its third-quarter 2026 earnings call on October 29, 2026, listed on the company's investor page at Eli Lilly.

Revenue growth meets valuation pressure

For investors, the key tension is visible in the gap between 47.70 percent year-over-year revenue growth in the second quarter of 2026 and the premium valuation attached to the stock. MarketBeat reported a trailing price-to-earnings ratio of 38.32 and a market capitalization of USD 1.08 trillion on its company page.

Trading stays near the yearly high

The primary-exchange quote was USD 1,163.58 at 9:40 a.m. ET on October 9, 2026, while the 52-week high stood at USD 1,292.65. At Lang & Schwarz, the euro quote was EUR 1,039.50 at 3:35 p.m. CEST on October 9, 2026, down 0.12 percent versus the EUR 1,040.80 prior close.
The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.